Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MedImmune LLC
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed aggressive B-cell DLBCL, including FL transforming to DLBCL \& Grade III FL
Relapsed from or refractory to at least one treatment containing rituximab or another anti-CD20 based immunotherapy combined with anthracycline- or anthracenedione-based chemotherapy
Eligible for ASCT
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Life expectancy of ≥ 12 weeks
Adequate hematological function
You may not be if
Any chemotherapy, radiotherapy, immunotherapy, biologic, investigational or hormonal therapy for treatment of lymphoma within 28 days prior to treatment
Previous cancer therapy for DLBCL other than anthracycline- or anthracenedione based chemoimmunotherapy, monotherapy rituximab prior to first line therapy and/or as a maintenance therapy, or limited field radiotherapy
Prior autologous or allogeneic SCT
New York Heart Association ≥ Class II congestive heart failure; Clinically significant abnormality on ECG
History of other invasive malignancy within 5 years except for localized/in situ, carcinomas such as cervical carcinoma in situ.
Evidence of active infection
Documented current central nervous system involvement by leukemia or lymphoma
Clareo Health | A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
